These results suggest that the activation pathway triggered by TPO is only partially affected by the antiplatelet therapy commonly used in patients with myocardial ischemia [40] and that platelet priming by TPO may represent a mechanism leading to therapeutic failure of antiplatelet agents. The gene discussed is TPO; the disease is myocardial ischemia.